Belgium UCLouvain Louvain Drug Research Institute (LDRI) and Netherlands MedTech Start-up Gilbert join efforts for improved therapy for Cystic Fibrosis Patients.
LDRI receives funding for the development of a long-acting PEGylated rhDNase for CF-treatment with reduced therapeutic burden.
Click here for the full text press release.
Gilbert is developing the next generation of soft mist inhalers based on a proprietary electrospray (Electro Hydrodynamic Atomization or EHDA) technology to redefine treatment for lung patients. Gilbert’s breath actuated smart precision inhaler creates a monodispersed soft mist aerosol, with a customizable droplet size enabling more precise targeting of drugs to desired regions of the lungs, which has the potential to improve the efficacy and safety of treatments. Electrospray enables gentle, efficient delivery of both small and large molecule therapies in both solution and suspension formulations.
Visit us at Gilbert | Redefining treatment for lung patients, follow us on Linkedin or contact us at info@gilbert.eu to learn if electrospray is suitable for your application.
Stay up-to-date with Gilbert’s latest news, vacancies and achievements by following us on social media.